Quality of Life Among Testicular Cancer Survivors

Rabin Medical Center330 enrolled

Overview

Testicular Cancer is the most prevalent malignancy among men between 20 and 34 years of age, with incidence rates rising in western countries including Israel. Cure rate of testicular cancer exceeds 90% with modern treatments. Thus issues such as quality of life (QoL), coping, effects on couple relationships, cognitive function, cognitive orientation and hormonal function become increasingly important. This study aims to assess all these issues using validated, reproducible questionnaires and hormonal plasma levels, and compare them between testicular cancer survivors and controls.

The study will be conducted in RMC, Beilinson and Golda. Eligible male patient list will be drawn from the Rabin Medical Center (RMC) operation rooms' data system. Patients will be contacted by their treating urologists over the phone or during follow-up visits and invited to take part in the research which will be conducted at RMC. The first stage of the study will include a validation of the EORTC QLQ-TC26 questionnaire in Hebrew. Patients and partners / spouses will sign informed-consent forms and fill out questionnaires during their visit, and blood samples will be drawn on the day of questionnaire completion or no longer than 1 month from it. Spouses will be given the choice of arriving with the patient and filling-in their questionnaires at RMC, or having them mailed to their homes. Research assistants will provide assistance with the questionnaires. Normal controls will be recruited among Tel Aviv University students, 'Achva' College students and RMS staff and asked to come to RMC for blood tests. Control subjects will be asked to answer the same cancer-related questionnaires as the patients, as fully as possible, unless the questions are irrelevant to them. The anticipated recruitment period will be approximately 36 months. Financial incentives: a compensation of 150 NIS will be offered to healthy participants coming to RMC for blood tests under this study. Duration of research participation: 1 or 2 encounters (the second for missing data or missing blood samples, and in the first 30 patients - for TC26 questionnaire re-validation by the EORTC requirements), during no longer than 1 month for each participant. Measurements will be compared across the patient and 2 control groups and their correlation to hormonal function assessed.

Study Type

OBSERVATIONAL

Enrollment

330

Interventions

QuestionnairesOTHER

Questionnaires: For examinee: European Organization for Research and Treatment of Cancer quality of life questionnaire of 30 items and testicular cancer module of 26 items (EORTC QLQ-30 + QLQ-TC-26), Multidimensional Coping Inventory, The Meaning Test for cognitive function, cognitive orientation questionnaires. For partner: Multidimensional Inventory of quality of life (QoL) for Adults, Multidimensional Coping Inventory.

Hormonal Function measurementOTHER

Plasma levels of: follicular stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), prolactin, free androgen index.

Eligibility

Sex: MALEMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: Group1: Testicular cancer long-term survivors * Male subjects between 2 to 10 years after testicular cancer diagnosis, who have completed treatment and are regarded as complete responders. * Able to give informed consent Group 2: Benign testicular conditions patients * Male subjects between 2 to 10 years after testicular surgery due to a benign condition. * Able to give informed consent Group 3: Healthy Controls * Healthy males * Able to give informed consent Partners of males from above 3 groups * Females or males * In a couple relationship with a man of 1 of the above groups, for 1 year or longer. * Able to give informed consent Exclusion criteria: Group1: Testicular cancer long-term survivors * Inability to answer questionnaires (i.e due to mental impairment). * Another malignancy, other than non-invasive skin basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). * Testicular cancer recurrence. Group 2: Benign testicular conditions patients * Inability to answer questionnaires. * Any history of malignancy other than non-invasive skin BCC or SCC. Group 3: Healthy Controls * Inability to answer questionnaires. * Any history of malignancy other than non-invasive skin BCC or SCC. * Any history of testicular surgery or diagnosed testicular problems in adulthood or childhood. Partners of males from above 3 groups \- Inability to answer questionnaires.